Tech Company Financing Transactions

Tvardi Therapeutics Funding Round

683 Capital, ArrowMark Partners and Palkon Capital Management participated in a $74 million Series B venture round for Tvardi Therapeutics. This venture round was announced on 6/24/2021.

Transaction Overview

Company Information

Company Status

Private & Independent

Industry

Biopharmaceutical

Mailing Address

2450 Holcombe Blvd. X
Houston, TX 77021
USA

Phone

(832) 413-1362

Website

www.tvarditherapeutics.com

Email Address

Not Recorded

Overview

Tvardi Therapeutics is a clinical stage, private biotechnology company developing a new class of breakthrough medicines for diverse cancers, chronic inflammatory diseases and fibrotic diseases. Founded in 2017 and based in Houston, Texas, the company is led by experienced entrepreneurs, innovative scientists and dedicated physicians.

Profile

Social Media

Company News

Facebook

YouTube

Management Team

Title

Name

Email & Social

Chief Executive Officer

Imran Alibhai

        

Chief Scientific Officer

Jeno Gyuris

        

VP - Bus. Development

Sofia de Achaval

        

VP - R & D

Jeffrey Larson

        

Browse more venture capital transactions:

Prev: 6/24/2021: Lender Compliance Technologies venture capital transaction
Next: 6/24/2021: Lower venture capital transaction

Share this article

Where The Data Comes From

We do our best to report on tech company VC transactions. VC transactions reported here come from a variety of public sources. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary